Compare CMCM & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCM | ACIU |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.5M | 213.3M |
| IPO Year | 2014 | 2016 |
| Metric | CMCM | ACIU |
|---|---|---|
| Price | $6.99 | $3.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 18.8K | ★ 444.5K |
| Earning Date | 11-26-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $151,517,306.00 | $5,482,957.00 |
| Revenue This Year | $14.27 | N/A |
| Revenue Next Year | $39.26 | $644.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 46.34 | N/A |
| 52 Week Low | $3.28 | $1.43 |
| 52 Week High | $9.44 | $4.00 |
| Indicator | CMCM | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 54.97 | 56.14 |
| Support Level | $6.29 | $3.32 |
| Resistance Level | $7.20 | $3.74 |
| Average True Range (ATR) | 0.28 | 0.22 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 79.86 | 66.67 |
Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.